49 related articles for article (PubMed ID: 23606319)
1. Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice.
Shin DH; Jiang H; Gillard AG; Kim D; Fan X; Singh SK; Nguyen TT; Sohoni SS; Lopez-Rivas AR; Parthasarathy A; Ene CI; Gumin J; Lang FF; Alonso MM; Gomez-Manzano C; Fueyo J
Mol Ther; 2024 Mar; 32(3):722-733. PubMed ID: 38311852
[TBL] [Abstract][Full Text] [Related]
2. A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer.
Kim KH; Dmitriev IP; Saddekni S; Kashentseva EA; Harris RD; Aurigemma R; Bae S; Singh KP; Siegal GP; Curiel DT; Alvarez RD
Gynecol Oncol; 2013 Sep; 130(3):518-24. PubMed ID: 23756180
[TBL] [Abstract][Full Text] [Related]
3. An autologous ex vivo model for exploring patient-specific responses to viro-immunotherapy in glioblastoma.
Stavrakaki E; van den Bossche WBL; Vogelezang LB; Teodosio C; Mustafa DM; van Dongen JJM; Dirven CMF; Balvers RK; Lamfers ML
Cell Rep Methods; 2024 Mar; 4(3):100716. PubMed ID: 38430913
[TBL] [Abstract][Full Text] [Related]
4. A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model.
Kim JW; Miska J; Young JS; Rashidi A; Kane JR; Panek WK; Kanojia D; Han Y; Balyasnikova IV; Lesniak MS
Mol Ther Oncolytics; 2017 Jun; 5():97-104. PubMed ID: 28573184
[TBL] [Abstract][Full Text] [Related]
5. The heterogeneous sensitivity of pediatric brain tumors to different oncolytic viruses is predicted by unique gene expression profiles.
Vazaios K; Stavrakaki Ε; Vogelezang LB; Ju J; Waranecki P; Metselaar DS; Meel MH; Kemp V; van den Hoogen BG; Hoeben RC; Chiocca EA; Goins WF; Stubbs A; Li Y; Alonso MM; Calkoen FG; Hulleman E; van der Lugt J; Lamfers MLM
Mol Ther Oncol; 2024 Jun; 32(2):200804. PubMed ID: 38694569
[TBL] [Abstract][Full Text] [Related]
6. Apoptin Regulates Apoptosis and Autophagy by Modulating Reactive Oxygen Species (ROS) Levels in Human Liver Cancer Cells.
Li Y; Zhu Y; Fang J; Li W; Li S; Liu X; Liu Z; Song G; Shang C; Cong J; Bai B; Sun L; Jin N; Li X
Front Oncol; 2020; 10():1026. PubMed ID: 32714864
[TBL] [Abstract][Full Text] [Related]
7. Combined therapy of colon carcinomas with an oncolytic adenovirus and valproic acid.
Bressy C; Majhen D; Raddi N; Jdey W; Cornilleau G; Zig L; Guirouilh-Barbat J; Lopez BS; Bawa O; Opolon P; Grellier E; Benihoud K
Oncotarget; 2017 Nov; 8(57):97344-97360. PubMed ID: 29228615
[TBL] [Abstract][Full Text] [Related]
8. Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma.
Rundle-Thiele D; Head R; Cosgrove L; Martin JH
Br J Clin Pharmacol; 2016 Feb; 81(2):199-209. PubMed ID: 26374633
[TBL] [Abstract][Full Text] [Related]
9. In vitro screening of clinical drugs identifies sensitizers of oncolytic viral therapy in glioblastoma stem-like cells.
Berghauser Pont LM; Balvers RK; Kloezeman JJ; Nowicki MO; van den Bossche W; Kremer A; Wakimoto H; van den Hoogen BG; Leenstra S; Dirven CM; Chiocca EA; Lawler SE; Lamfers ML
Gene Ther; 2015 Dec; 22(12):947-59. PubMed ID: 26196249
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic adenoviruses: A thorny path to glioma cure.
Ulasov IV; Borovjagin AV; Schroeder BA; Baryshnikov AY
Genes Dis; 2014 Dec; 1(2):214-226. PubMed ID: 25685829
[TBL] [Abstract][Full Text] [Related]
11. Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization.
Conrad C; Miller CR; Ji Y; Gomez-Manzano C; Bharara S; McMurray JS; Lang FF; Wong F; Sawaya R; Yung WK; Fueyo J
Cancer Gene Ther; 2005 Mar; 12(3):284-94. PubMed ID: 15650766
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment.
van den Bossche WBL; Kleijn A; Teunissen CE; Voerman JSA; Teodosio C; Noske DP; van Dongen JJM; Dirven CMF; Lamfers MLM
Neuro Oncol; 2018 Oct; 20(11):1494-1504. PubMed ID: 29796615
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic adenoviruses for the treatment of brain tumors.
Gomez-Manzano C; Fueyo J
Curr Opin Mol Ther; 2010 Oct; 12(5):530-7. PubMed ID: 20886384
[TBL] [Abstract][Full Text] [Related]
14. [Oncolytic adenoviruses in anti-cancer therapy: current status and perspectives].
Sviatchenko VA; Tarasova MV; Netesov SV; Chumakov PM
Mol Biol (Mosk); 2012; 46(4):556-69. PubMed ID: 23113343
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic concentrations of anti-epileptic drugs do not inhibit the activity of the oncolytic adenovirus Delta24-RGD in malignant glioma.
de Jonge J; Berghauser Pont LM; Idema S; Kloezeman JJ; Noske D; Dirven CM; Lamfers ML
J Gene Med; 2013; 15(3-4):134-41. PubMed ID: 23606319
[TBL] [Abstract][Full Text] [Related]
16. The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells.
Berghauser Pont LM; Kleijn A; Kloezeman JJ; van den Bossche W; Kaufmann JK; de Vrij J; Leenstra S; Dirven CM; Lamfers ML
PLoS One; 2015; 10(5):e0127058. PubMed ID: 25993039
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
